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INTRODUCTION. High-grade prostatic intraepithelial neoplasia (HGPIN) is a recognized
precursor stage of PCa. Men who present HGPIN in a first prostate biopsy face years of active
surveillance including repeat biopsies. This study aimed to identify non-invasive prognostic
biomarkers that differentiate early on between indolent HGPIN cases and those that will
transform into actual PCa.
METHODS. We measured the expression of 21 candidate mRNA biomarkers using
quantitative PCR in urine sediment samples from a cohort of 90 patients with initial diagnosis
of HGPIN and a posterior follow up of at least two years. Uni- and multivariate statistical
analyses were applied to analyze the candidate biomarkers and multiplex models using
combinations of these biomarkers.
RESULTS. PSMA, PCA3, PSGR, GOLM, KLK3, CDH1, and SPINK1 behaved as predictors for
PCa presence in repeat biopsies. Multiplex models outperformed (AUC¼ 0.81–0.86) the
predictive power of single genes, including the FDA-approved PCA3 (AUC¼ 0.70). With a
fixed sensitivity of 95%, the specificity of our multiplex models was of 41–58%, compared to
the 30% of PCA3. The PPV of our models (30–38%) was also higher than the PPV of PCA3
(27%), suggesting that benign cases could be more accurately identified. Applying statistical
models, we estimated that 33% to 47% of repeat biopsies could be prevented with a multiplex
PCR model, representing an easy applicable and significant advantage over the current gold
standard in urine sediment.
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DISCUSSION. Using multiplex RTqPCR-based models in urine sediment it is possible to
improve the current diagnostic method of choice (PCA3) to differentiate between benign
HGPIN and PCa cases. Prostate. # 2015 Wiley Periodicals, Inc.
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INTRODUCTION
Prostate cancer (PCa) is the most commonly
diagnosed cancer and a major cause of
cancer-related death among men in economically
developed countries [1]. The current screening
method to diagnose PCa is based on the measure-
ment of serum prostate specific antigen (PSA) levels
and a digital rectal examination (DRE), whereas the
decisive diagnosis is based on the result of the
transrectal ultrasound-guided prostate biopsies.
Adoption of widespread PSA-based screening dur-
ing the late 1980s has substantially reduced mortality
rates. However, the use of screening PSA remains
controversial due to the high rates of overdiagno-
sis [2]. Nowadays a significant proportion of men are
diagnosed with a PCa that would have remained
undetected in the absence of screening. In these cases,
by definition, treatment would not improve health
outcomes for these men (overtreatment) [3]. Instead of
applying a curative aggressive treatment, active sur-
veillance is gaining acceptance as an alternative initial
management strategy for men with low-risk PCa [4].
It has been proven that men who have an initial
non-cancerous biopsy diagnosis remain at risk of PCa,
especially if the initial diagnosis included suspicious
lesions [5]. There is evidence that many prostate
cancers are preceded by or accompanied with a
pre-malignant change in the epithelial cells, known as
prostatic intraepithelial neoplasia (PIN). This condition
is characterized by progressive proliferation of cytolog-
ically atypical or dysplastic epithelial cells within
architecturally benign-appearing glands and acini [6].
PIN is recognized as a continuum between
low-grade and high-grade forms, with high-grade PIN
(HGPIN) thought to represent a likely immediate
precursor of early invasive carcinoma [7]. HGPIN
resembles PCa in its cytological appearance and also at
the molecular level, showing a pattern of gene and
protein expression for various PCa biomarkers that is
either similar to PCa or “intermediate” between
tumoral and benign prostate tissue [8].
These premalignant lesions are strongly predictive
of the presence of carcinoma. It has been shown that
PCa discovered after an initial HGPIN diagnosis on
biopsy are more likely to be organ confined, yet of
similar grade, compared with cases diagnosed as PCa
on the first biopsy. These findings likely reflect a
scenario in which the PCa were missed on the initial
biopsy as a result of smaller size [9]. Recent studies
estimated that around 22% of all patients diagnosed
with HGPIN in the first biopsy will be diagnosed with
PCa in consecutive repeat biopsies [10]. This percent-
age has decreased over the last years, mainly due to
increased needle biopsy core sampling, which detects
many associated cancers on initial biopsy, such that
re-biopsy, even with good sampling, does not detect
many additional cancers. However, this percentage is
still a bit higher than the risk reported in the literature
for repeat biopsy following a benign diagnosis, and
clinical and pathological parameters do not help
stratify which men with HGPIN are at increased risk
for a cancer diagnosis [11]. Consequently, men with
HGPIN usually undergo a close clinical follow-up over
several years, including measurement of serum PSA,
DRE, ultrasound and repeat biopsies [12]. Evidently,
the majority of the patients (78%) will have negative
results year after year, thus many repeat biopsies could
be avoided if clinicians were provided with an accurate
preferably non-invasive predictive test for determining
PCa presence. For this purpose biomarkers that distin-
guish between pre-malignant lesions such as HGPIN
and PCa are urgently needed.
Several attempts have been made in the past to
improve the current management of HGPIN patients.
For instance, the number of positive HGPIN cores at
the moment of diagnosis has been associated with the
risk of cancer, suggesting that patients with unifocal
HGPIN should be managed expectantly, whereas
those with multifocal HGPIN could benefit from a
more aggressive surveillance including repeat biop-
sies [13]. Moreover, overexpression of certain mole-
cules in HGPIN tissue has been found to correlate
with the likelihood of finding PCa in subsequent
biopsies. One of these predictors is the TMPRSS2:ERG
gene fusion. Park et al. assessed the presence of this
molecular rearrangement by immunohistochemistry
on prostate biopsies, showing that patients with ERG
overexpression were more likely to develop PCa [14].
Moreover, prostate tumor overexpressed 1 (PTOV1)
and alpha-methylacyl-CoA racemase (AMACR) have
also been found overexpressed in HGPIN lesions
adjacent to PCa in comparison with isolated
HGPIN [15,16]. Markers in biological fluids have also
been described. For example, an increased serum level
of early prostate cancer antigen (EPCA) has been
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associated with a higher cancer risk in men with
isolated HGPIN [17].
Previous research from our group showed that
PCA3, PSGR (OR51E2), and PSMA (FOLH1) gene
expression in urine sediment could be useful bio-
markers for the detection of PCa in benign prostatic
hyperplasia (BPH) cases. Although with a lower
efficacy, we observed in these studies that PCA3 could
also detect PCa in patients with a previous diagnosis
of HGPIN [18,19].
Among all the first prostate biopsies performed in
the Vall d’Hebron Hospital, 42.8% are diagnosed with
HGPIN (data from the years 2007–2010). Those
patients undergo an intensive follow-up including
one or more repeat biopsies. In order to prevent
unnecessary biopsies, our objective in this study was
to find a gene profile in urine sediment that accurately
identifies “true” HGPIN cases separating them from
HGPIN cases with undetected PCa found in repeat
biopsies. For this purpose, a list of markers previously
associated with PCa were analyzed in a unique set of
urine samples from 90 patients diagnosed with
HGPIN in a first biopsy and who subsequently under-
went a clinical follow-up for several years until PCa
presence was confirmed or regarded as absent.
MATERIALS AND METHODS
Patients
This study was approved by the institutional review
board of the Vall d’Hebron Hospital. All urine samples
were obtained from the Department of Urology of the
Vall d’Hebron Hospital in Barcelona between 2008 and
2013 and were taken from patients subjected to a repeat
prostate biopsy because of a previous biopsy result of
HGPIN. Their first biopsy was recommended due to
increased serum PSA levels (>4ng/ml) and/or an
abnormal diagnostic DRE. Patients with other known
tumors and/or previous PCa therapies were excluded
from the study. Written informed consent was obtained
from all the study participants and samples were
coded to ensure sample tracking and confidentiality on
patient/donor identity.
The diagnosis of all patients was achieved by trans-
rectal ultrasound (TRUS)-guided prostate biopsy. Biop-
sies were performed using an end-fire ultrasound
transducer Falcon 2101 (BK Medical, Herlev, Denmark)
and an automatic 18 gauge needle (Bard, Covington,
GA). The minimum number of cores removed in every
procedure was 10, and between 1 and 8 additional
cores were obtained based on age and total prostate
volume, according to the Vienna nomogram.
In the scope of this study, a total of 1,056 first
prostate biopsies were performed. In 402 cases, PCa
was detected and, of the remaining 654 PCa-free cases,
280 presented HGPIN (42.8%). From these 280 HGPIN
cases, 173 agreed to a repeat biopsy in a 1–3 years time
period, independently of their serum PSA levels
evolution. It was possible to collect urine samples
previous to the second prostate biopsy in 124 of these
patients. The final study population analyzed consisted
of 114 men, with a first biopsy result of HGPIN, who
underwent at least one additional repeat prostate
biopsy. In 24 cases, the second or subsequent biopsies
revealed the presence of PCa, whereas in the rest of
cases the patients were diagnosed with a benign
pathology (Table I). All biopsy materials were eval-
uated by the same experienced uropatholgist.
Sample Preparation
Urine samples (30–50 ml) were collected after DRE
within days before a repeat biopsy. Urine was
collected in urine collection cups, kept on ice, trans-
ported to the lab and processed within 2 hr of its
TABLE I. Clinico-Pathological Conditions of Patients Included in the Study
Benign cases n¼ 81 average (range, %) PCa cases n¼ 19 average (range, %)
Age, years 64.6 (49–82) 67.6 (54–80)
PSA, ng/ml 7.2 (2.4–18.0) 6.9 (4.4–14.0)
Free PSA, ng/ml 1.4 (0.4–5.3) 1.1 (0.4–2.9)
Free/total PSA ratio 0.19 (0.04–0.39) 0.16 (0.07–0.34)
PSA density (PSAD) 4.7 (0.03–126.0) 0.2 (0.1–0.3)
Prostate volume, ml 60.6 (15.6–260.0) 49.4 (18.9–103.0)
No. cores HGPIN in 1st biopsy 2.9 (1–7) 3.8 (1–8)
Time until 2nd biopsy, months 22.6 (12–35) 24.1 (14–42)
Gleason score< 7 – 10 (52.6%)
Gleason score¼ 7 – 7 (36.8%)
Gleason score> 7 – 2 (10.5%)
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collection. The urine samples were centrifuged at
2500g for 10min at 4°C. Cellular pellets were
washed twice with cold PBS and finally resuspended
1:5 in RNALater(Ambion; Life Technologies/Thermo
Fisher Scientific, Waltham, MA) and stored at 80°C
until RNA extraction.
RNA Extraction and RT-qPCR
Total RNA of the cellular fraction was extracted
using the QIAmp Viral Kit (Qiagen, Hilden, Ger-
many), following the manufacturer’s instructions.
Reverse transcriptase PCR of extracted RNA was
conducted to determine expression of six endoge-
nous genes (Table II) and 14 target genes (Table III).
cDNA obtained from the reverse transcription was
pre-amplified using RealTime ready cDNA
Pre-Amp Master, in combination with RealTime
ready Pre-Amp Primer Pools (Roche Applied Sci-
ence, Indianapolis, IN).
All RT-qPCR reactions were carried out in triplicate
on RealTime ready custom qPCR plates (Roche
Applied Science) and fluorescent signals were meas-
ured in a LightCycler 480 II (Roche Applied Science).
Data analysis was carried out using the LightCycler
480 software (v. 1.5).
Differential Expression Analysis
From the initial set of 114 samples, samples with
KLK3 Ct values> 35 and/or geometric mean of all
Ct values> 33 were excluded due to a low amount of
cDNA. To the final cohort, outlier detection was
performed by computing the Kolmogorov–Smirnov
statistic Ka between each sample’s distribution and
the distribution of the pooled data.
TABLE III. Parameters Calculated for Each One of the
PCa Biomarkers. AUC Value, PPV, NPV, Specificity and
Estimated Percentage of Saved Biopsies are Shown






PSMA (isoforms 1, 2, 3, 4, 5) 0.69 0.65
PSMA (isoforms 1, 2, 3, 4) 0.71 0.67
PSMA (isoforms 1, 3, 5) 0.66 0.61
PSMA (isoforms 3, 4) 0.69 0.65






PSMA (isoforms 1, 2, 3, 4, 5) 0.69 0.65
PSMA (isoforms 1, 2, 3, 4) 0.71 0.67
TABLE II. Target Genes for the Detection of PCa in Patients With a Previous Diagnosis of HGPIN. A Total of Seven
Genes Show Significant P-Values: CDH1, PSMA, GOLM1, KLK3, PSGR, PCA3, and SPINK1
Symbol Name P-value*
ABCA5 ATP-binding cassette, sub-family A (ABC1), member 5 0.335
AGR2 Anterior gradient 2 0.464
AURKA Aurora kinase A 0.748
CDH1 Cadherin 1, type 1, E-cadherin (epithelial) <0.001
CHKA Choline kinase alpha 0.858
EN2 Engrailed homeobox 2 0.726
GOLM1 Golgi membrane protein 1 0.004
KLK3 Kallikrein-related peptidase 3/prostate specific antigen (PSA) 0.032
PCA3 Prostate cancer associated 3 0.008
PSGR Olfactory receptor, family 51, subfamily E, member 2/prostate specific G-couple receptor <0.001
PSMA Folate hydrolase 1/prostate-specific membrane antigen (isoforms 1, 2, 3, 4, 5) 0.011
PSMA Folate hydrolase 1/prostate-specific membrane antigen (isoforms 1, 2, 3, 4) 0.005
PSMA Folate hydrolase 1/prostate-specific membrane antigen (isoforms 1, 3, 5) 0.032
PSMA Folate hydrolase 1/prostate-specific membrane antigen (isoforms 3, 4) 0.012
S100A9 S100 calcium binding protein A9 0.960
SPINK1 Serine peptidase inhibitor, kazaltype 1 0.042
TIMP4 TIMP metallopeptidase inhibitor 4 0.113
*The P-value corresponds to the Mann–Whitney test results.
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Relative gene expression was calculated by the
DDCt method. The endogenous reference gene for
the data normalization was selected from a list of
six commonly used housekeeping genes: Hypo-
xanthine Phosphoribosyltransferase 1 (HPRT1),
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH),
Delta-Aminolevulinate Synthase 1 (ALAS1), TATA Box
Binding Protein (TBP), Beta-2-microglobulin (B2M), Kal-
likrein-3/Prostate Specific Antigen (KLK3). The selection
criteria was the lowest coefficient of variation, lowest Ct
geometric mean, without differences between groups
(calculated by Mann–Whitney test) and with an area
between the receiver-operating characteristic (ROC)
curve and the no-discrimination line (area under the
curve; AUC) close to 0.5.
Statistical Analysis
Univariate tests and univariate and multivariate
logistic regressions were used to examine associations
between PCa diagnostic status and testing genes. For
this purpose, Mann–Whitney test [20] and Random
Forest method [21] were used for variable importance
measurement. Both methodologies were evaluated by
Leave-one-out cross-validation (LOOCV) to correct
the bias estimated from them. Conjointly, ROC analy-
sis was used to assess genes performance (with 95%
confidence interval).
All possible multiplex models were created using
combinations of the most significant genes obtained
in the univariate analysis and multivariate logistic
regression was applied to them. In order to obtain
better models, Akaike information criterion [22] based
backward selections were used to drop insignificant
terms in all the resulting models via stepwise general-
ized linear models [23].
The percentage of biopsies potentially avoided by
the use of the proposed biomarkers was calculated by
adding up the number of true negatives and the




All patients enrolled in the study were men under-
going repeat prostate biopsy to rule out PCa when
HGPIN was previously identified. Urine was
obtained directly after DRE, and urinary cells were
pelleted and used for RNA expression levels analysis.
For the initial sample cohort studied, 90 out of the 114
specimens survived initial quality standards and
yielded sufficient prostate derived cells (KLK3 Ct
value 29) or overall amount of RNA (high geometric
mean of all Ct values 27) for further analysis,
corresponding to an informative specimen rate of
78.9% (benign 78.9% and PCa 21.1%).
This final cohort was analyzed for outliers detec-
tion, showing that none of the remaining samples
should be considered as an outlier (Fig. 1).
Data Normalization
Urine contains a highly variable mixture of cells of
different origins and, to date, there is no consensus
about the best way to normalize gene expression data
retrieved from this source. For that reason, we first
sought to determine an optimal endogenous reference
gene that can be used for normalization of target gene
expression. For this purpose, we assayed five universal
housekeeping genes ALAS1, B2M, GAPDH, HPRT1,
and TBP, in addition to the prostate-specific KLK3, in
the total final cohort of 90 samples.
Statistical analysis of the endogenous genes expres-
sion showed that the mRNA that best fit the criteria of
stability that represented minimal-differences between
all groups was TBP (Suppl. Table SI). Therefore, this
gene was chosen for the standardization in our
samples. Notably, we observed in our cohort that the
commonly used normalizing gene KLK3 actually
behaved as a biomarker itself, As its levels seemed to
be significantly increased in the confirmed PCa sam-
ples. For this reason, KLK3 was subsequently included
in the group of target genes for further evaluation.
Target Genes Expression Analysis
Having established a suitable endogenous reference
gene we compiled a list of previously reported PCa
urinary biomarkers (PCA3, PSGR, PSMA, ABCA5,
AGR2, GOLM1, SPINK1, and EN2) [19,24–28] supple-
mented with additional markers that were selected
because of their known relation with PCa tissue
(CDH1, CHKA, S100A9, TIMP4, and AURKA) [29–33]
and including the previously discussed KLK3. For
PSMA four different primer pairs that detect specific
combinations of known isoforms were used. Using
univariate analysis, differences in the mean expression
of all listed genes between PCa (n¼ 19) and benign
HGPIN cases (n¼ 71) were studied. Using this
approach, we demonstrated significant differential
expression (P< 0.05) of PCA3, PSMA, PSGR, KLK3,
GOLM1, CDH1, and SPINK1 (Table II).
Before proceeding with the next steps of the study,
all significant markers were cross-validated using the
LOOCV method. The genes CDH1, PSMA, GOLM1,
KLK3, PSGR, and PCA3 were selected for further
characterization, under the criterion of all individual
outcomes being significant. All of these genes
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appeared overexpressed in PCa urine samples when
compared to urine from patients presenting isolated
HGPIN (Fig. 2a). The AUCs for these markers indi-
vidually ranged from 0.66 to 0.77. Fixing the sensitiv-
ity at 95%, the obtained specificities for the individual
markers ranged between 24% and 37% (Table III).
Then, a multivariate regression analysis was
applied, to test whether the variables could have a
Fig. 1. Outliers detection in the final cohort of 90 urine sediment samples. (a) Boxplots representing distributions of the signal intensity
registered for each sample (light gray for benign samples, dark gray for PCa samples). Boxes are expected to present similar positions and widths;
if the distribution of a sample is very different from the others, this may indicate an experimental problem. (b) Bar chart of the Kolmogorov–
Smirnov statistic Ka, the outlier detection criterion from (a). Based on the distribution of the values across all samples, a threshold of 1.18 was
determined, which is indicated by the vertical line in the right. None of the samples exceeded the threshold and was considered an outlier.
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Fig. 2. Characterization of RNA biomarkers and biomarker panels in urine for PCa diagnosis in HGPIN patients. (a) RT-qPCR for 14
candidate biomarkers was performed on urinary sediment cDNA from patients referred for a repeat biopsy after a previous diagnosis of
HGPIN. Only biomarkers that were significant predictors for PCa (see Table III) are shown. Boxplots represent the expression levels for
each one of the genes. All genes present an increased expression in patients with PCa (dark gray) compared to patients with a benign
condition (light gray). Target genes expression was normalized following the DDCt method using TBP as endogenous reference. The
indicated P-values correspond to the univariate analysis (Mann–Whitney test) results. Statistical significance is represented as *P< 0.05,
**P< 0.01, ***P< 0.001. (b) Multivariate regression analysis resulted in a number of multiplex models (see Suppl. Table I), of which the
best three were selected. These models consist of combinations of KLK3, PSMA, PSGR, CDH1, and GOLM1. ROC curves were generated
according to the predicted probabilities derived from each one of the models. All the multiplex models (gray lines) present a higher AUC
than PCA3 alone (black dotted line). (c) Same as (b), but LOOCV results were used to generate the curves. The AUC of the LOOVC
models are also greater than the AUC of LOOCV PCA3.
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better performance when combined in a multiplex
model. This analysis resulted in a total of 36 possible
multiplex models that can distinguish between benign
conditions and PCa better than any of the individual
target genes (Suppl. Table II).
The most promising three models out of the 36
were selected based on overall performance values
(Fig. 2b, c, and Table IV), and further evaluated. Each
one of these yhree putative models greatly outper-
formed PCA3 (multiplex models AUC¼ 0.81–0.86 vs.
PCA3 AUC¼ 0.70), as well as all the other assayed
target genes when used alone, for the detection of
PCa. When fixing the sensitivity at 95%, the obtained
specificities ranged from 41% to 58%, which is
significantly higher compared to the 30% of PCA3, the
current gold-standard for diagnosis in urine. The PPV
and NPV ranged from 30% to 38%, and from 97% to
98%, respectively. PCA3 has a similar NPV, indicating
that both tests are equally reliable for discarding PCa
in case of a negative result. However, the lower PPV
of PCA3 (27% vs. 38%) indicates that PCA3 misclassi-
fies a higher amount of benign cases by giving a
positive result, which translates into a higher number
of biopsies that need to be practiced in follow up.
DISCUSSION
High-grade prostatic intraepithelial neoplasia
(HGPIN) is associated with an increased probability for
developing PCa or co-existence of undetected PCa. For
this reason, the diagnosis of HGPIN automatically
guarantees intensive surveillance of suspect PCa
patients over the years who must undergo multiple
repeat biopsies. However, only a small fraction of these
patients will eventually be diagnosed with PCa or
require active treatment. Consequently, a great number
of the practiced invasive repeat biopsies are unneces-
sary, causing pointless discomfort to the patient and
providing an extra expense to health care systems that
are already heavily burdened. Here we developed and
tested a simple qPCR-based non-invasive approach to
differentiate true HGPIN cases from those at risk of
hidden (i.e., undetected) PCa. To this end, we analyzed
the expression of 14 candidate mRNA markers in urine
samples sediment of a fully annotated clinical cohort of
90 patients and compared this to the current gold
standard (i.e., FDA-approved PCA3).
In the first place, we aimed to establish a good data
normalization strategy. For this purpose several
housekeeping genes were analyzed, alongside the
commonly used for normalization of urine data in
PCa studies KLK3. It became apparent that KLK3
presents differences between groups, being able to
differentiate PCa from HGPIN patients. One possible
explanation for this unexpected result is that patients
with a negative biopsy tend to have fewer cells of
prostatic origin and therefore have less KLK3 in their
post-DRE urine than malignant counterparts. This
TABLE IV. Multiplex Models of RNA Biomarkers Outperform PCA3 for the Detection of PCa in HGPIN Patients
Referred for Repeat Biopsy. All the Multiplex Models Present a Higher AUC, PPV, NPV and Specificity Than PCA3
Alone, and They Could Also Help Avoiding a Higher Number of Unnecessary Biopsies. After LOOCV, the Multiplex












1 KLK3þPSMA (isoforms 3, 4)þPSMA
(isoforms 1, 3, 5)þPSGRþCDH1
0.86 38 98 58 47
2 KLK3þPSMA (Isoforms 3, 4)þPSMA
(isoforms 1, 3, 5)þPSGRþGOLM1
0.84 37 98 56 46
3 KLK3þPSMA (isoforms 3, 4)þPSGRþCDH1 0.81 30 97 41 33
- PCA3 0.70 27 96 30 24











1 KLK3þPSMA (isoforms 3, 4)þPSMA
(isoforms 1, 3, 5)þPSGR þ CDH1
0.78 29 97 38 31
2 KLK3þPSMA (isoforms 3, 4)þPSMA
(isoforms 1, 3, 5)þPSGRþGOLM1
0.77 30 97 41 33
3 KLK3þPSMA (isoforms 3, 4)þPSGRþCDH1 0.77 29 96 37 30
- PCA3 0.66 25 95 25 2
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may relate to prostate cancer biology as loss of
cell-cell contacts in developing cancer may facilitate
shedding of prostate epithelial cells into the urine [34].
The increased levels of KLK3 in PCa patients may
thus cause researchers to erroneously discard poten-
tial biomarkers that follow the same pattern of
expression as KLK3. We propose that reference genes,
which are constitutively expressed by all cells such as
TBP, are better alternatives.
The core of this project consisted on the analysis of
the expression levels of a list of 14 candidate bio-
markers, of which PCA3, PSMA, PSGR, KLK3, GOLM1,
CDH1, and SPINK1 were found to be overexpressed in
PCa when compared to isolated HGPIN cases. In the
context of PCa detection, the clinical utility of a PCA3
gene-based molecular assay in urine has been exten-
sively demonstrated, and it is currently utilized in a
commercially available test under the name PRO-
GENSA1 PCA3 that was approved by the US Food
and Drug Administration (FDA) in 2012 [35,36]. In this
assay, PCA3 and KLK3 mRNAs are quantified, and the
PCA3 Score is calculated as the ratio of PCA3 and
KLK3 (PCA3 mRNA/KLK3 mRNA 1000). In a recent
study including 177 patients undergoing repeat biopsy,
the reported sensitivity, specificity, predictive positive
value (PPV), and negative predictive value (NPV) of
PCA3 Score (cut-off 20) in PCa diagnosis were 91.7,
25.6, 31.5, and 89.5%, respectively. In this cohort, the
use of PCA3 measurements could have avoided 21% of
repeat biopsies [37]. In our hands, using a cohort of 90
patients, the specificity, PPV and NPV values of PCA3
at a fixed sensitivity of 91.7% were of 30, 26, and 93%,
respectively, while 25.1% of the repeat biopsies could
had been avoided. Therefore, our results in an inde-
pendent cohort are comparable to previously published
data underlying the accuracy of our measurements.
Notably however, several of the genes we assayed in
this study strongly outperformed PCA3 for the detec-
tion of PCa in repeat prostate biopsies. Specially, CDH1
and PSGR show higher AUC values compared to
PCA3 (0.77 and 0.75 vs. 0.70).
Finally, multiplex models combining the genes over-
expressed in PCa were developed, resulting in an
improvement of the predictive power. It is worth
noting that our multiplex models if validated could
save anywhere between a third and almost half
(33–47%) of the repeat biopsies currently practiced,
representing a significant improvement over the
FDA-approved PCA3 with only 21% of biopsies saved
(Table IV). In data calculated for the United States, the
incidence of isolated HGPIN averages 9% (range,
4–16%) of prostate biopsies, representing 115,000 new
cases of HGPIN without cancer diagnosed each
year [7]. This means that, according to the calculated
percentages, it would be possible to save approxi-
mately between 37,950 and 54,050 repeat biopsies
annually, a number that is only expected to increase
due to an aging population. For this calculation, we
used the formula: % of biopsies saved¼ true negatives
(test negative and biopsy negative)þ false negatives
(test negative and biopsy positive)/all patients.
Although this would imply that one could save a
biopsy by incorrectly classifying (test negative and
biopsy positive) a patient as not having PCa, the
number of false negatives to obtain a sensitivity of 95%
is negligible (in this study one patient; NPV 97%).
A possible limitation of our study is that the second
biopsy outcome was used as the definitive diagnosis
of the patient. However, there is still a small chance of
missing a PCa in this second biopsy. In some cases,
PCa is finally diagnosed after a third or even subse-
quent biopsies. For this reason, we cannot discard the
possibility of having misclassified a small number of
patients in our study. Furthermore, although very
promising results have been obtained, a larger sample
size would be needed to further validate the best
predictive models.
In the last years, a variety of techniques have
appeared for the optimization of prostate biopsies, in
an attempt to minimize the percentage of
false-negative results. TRUS-guided biopsy is still the
standard approach; however, this technique has mul-
tiple limitations owing to the operator’s inability in
most cases to directly visualize and target prostate
lesions. Magnetic resonance imaging (MRI) of the
prostate can overcome many of these limitations by
directly depicting areas of abnormality and allowing
targeted biopsies [38]. It would be highly interesting
to validate our results in a new set of patients who
have also undergone a MRI-guided biopsy, in order to
determine (i) whether these two methods can comple-
ment each other, (ii) if our biomarkers profile could be
an useful tool to decide about performing a MRI, and
(iii) the cost and specificity of these two approaches,
always aiming to define a reliable diagnostic method
that can help prevent unnecessary biopsies.
Alternative biomarkers-based tests are also being
developed and investigated, with the aim of provid-
ing a more accurate means of PCa detection in repeat
prostate biopsy cohorts. A promising new test based
on serum PSA is the Prostate Health Index (PHI),
which has recently been approved in the United
States, Europe, and Australia. PHI is a mathematical
formula that combines total PSA, free PSA and the
[-2] form of proPSA (the inactive precursor of PSA),
into a single score that can be used to aid in clinical
decision-making [39]. Several studies have docu-
mented the performance of PHI in large groups of
patients, reporting AUC values ranging from 0.68 to
0.74 [40–45] which is smaller compared to our multi-
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plex models (AUC¼ 0.81–0.86) and similar to PCA3
(AUC¼ 0.70).
Epigenetic tests performed on biopsy material have
also been reported as promising independent predic-
tors of PCa risk to guide decision making for repeat
biopsy. An assay involving the epigenetic profile of
GSTP1, APC, and RASSF1 resulted in a NPV of 88%.
As the multiplex panels presented in this study have
a higher NPV (97–98%), combining the outcome of
this epigenetic assay may help to further decrease the
number of unnecessary repeat prostate biopsies [46].
Finally, it is also worth mentioning the use of
nomograms for the prediction of PCa. Benecchi et al.
described a predictive model that incorporates clinical
data and PSA kinetic data, showing outstandingly
good results (AUC¼ 0.856) [47]. This nomogram
performs extremely well in the general population
suspicious of PCa (with at least one negative biopsy),
but its utility in the specific case of HGPIN patients
remains to be elucidated. For evaluation of clinical
utility of our results, a nomogram with performance
statistics is planned to be generated in independent
cohorts.
Porpiglia et al. performed a study comparing the
predictive value of PCA3, MRI-guided prostate biopsy
and PHI in the repeat biopsy setting. They found that
the most significant contribution for PCa detection
was provided by MRI-guided biopsies, with an AUC
of 0.94 and a specificity of 57% (at a 95% sensitivity).
In fact, the inclusion of PCA3 and/or PHI to models
containing MRI-guided prostate biopsy did not sub-
stantially improve the net benefit. These results
indicate that MRI-guided prostate biopsy has a high
diagnostic accuracy in identifying patients with PCa
in the repeat biopsy setting; however, its combination
with minimally-invasive biomarker tests such as
PCA3 or PHI does not improve the overall perform-
ance [48]. It is clear that the prostate biopsy result will
continue to be the gold-standard for PCa diagnosis in
the near future. However, implementation of an
accurate non-invasive biomarker-based test as the one
evaluated here can significantly reduce the frequency
of invasive and expensive procedures when validated
in independent cohorts. There is a reason to be
optimistic for successful validation since in our cohort
the currently approved PCA3 test showed a similar
performance as reported by others [37]. Combined
with the knowledge that our test can be easily
implemented in daily care many erroneously sus-
pected PCa patients could benefit from this work.
CONCLUSIONS
In summary, we have shown that a multiplexed
RT-qPCR assay on urine sediments from patients
presenting for a repeat prostate biopsy due to a
diagnosis of HGPIN has a significantly improved
predictive ability when compared to PCA3 or any other
assayed gene when used alone. Further evaluation and
validation of these biomarkers in larger and independ-
ent cohorts is thus warranted. In the future, a multi-
plexed urine-based diagnostic test for PCa with a
higher specificity but the same sensitivity as the serum
PSA test could be used for an easier management of
patients with HGPIN, aiding clinicians to select
patients that will benefit from a repeat biopsy.
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